Short Term Real Life Data of Intravitreal Bevacizumab, Ranibizumab and Aflibercept Therapy in Diabetic Macular Edema

Author: saadet gültekin ırgat (Turkey)

Co-authors: Orhan Altunel, Alpaslan Koc, Fatih Özcura

Purpose

To present the short-term effects of intravitreal bevacizumab, ranibizumab and aflibercept on diffuse diabetic macular edema (DME) with real life data under varying payment conditions.

Setting/Venue

This study retrospective study conducted at Kütahya Health Science University School of Medicine

Methods

One hundred and four eyes of 86 patients with DME were included in the study. In the groups in which 3 doses of intravitreal treatment is planned for DME; before the treatment, best corrected visual acuity (BCVA), central macular thickness (CMT), fundus angiography (FA) and complete ophthalmologic examination were performed. The examinations were repeated at 1, 2 and 3 months.

Results

The mean age of the patients was 63.19 ± 7.8. The mean BCVA before injection was 0.43 in the bevacizumab group, 0.52 in the ranibizumab group and 0.53 logMAR in the aflibercept group (p = 0.258). CMT before injection was 540 ± 75, 497 ± 70, 517 ± 105 (p = 0.117) in the bevacizumab, ranibizumab and aflibercept groups, respectively. After three doses of injection, BCVA was 0.30 in the bevacizumab group, 0.23 in the ranibizumab group and 0.30 logMAR in the aflibercept group (p = 0.397).After three doses of drug injections, CMT values were found to be 429 ± 90 μm in the bevacizumab group, 348 ± 48 μm in the ranibizumab group, and 338 ± 61 μm in the aflibercept group (p <0.001). The least decrease in CMT was in the bevacizumab group (111 μm, p = 0.012). In the aflibercept and ranibizumab groups, a decrease of 178 μm and 166 μm was found in CMT, respectively, and there was no statistically significant difference between the two agents (p = 0.862).

Conlusions

Significant improvement was observed in BCVA and CMT. The improvement in CMT was greater in the aflibercept and ranibizumab groups than in the bevacizumab group.

Financial Disclosure

No have financial relations